ResMed Inc. vs Verizon Communications Inc — how do they compare? ResMed Inc. trades at $229.4 (market cap $31.89B), while Verizon Communications Inc trades at $41.15 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 6× ResMed Inc.'s market cap, and Verizon Communications Inc pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Verizon Communications Inc for 109 Days on average.
| RMD | VZ | |
|---|---|---|
Market Cap | $31.89B | $192.57B |
Volume | 618,314 | 20,940,094 |
Sector | Health | Media |
52-Week High | $277.88 | $51.45 |
52-Week Low | $182.82 | $38.40 |
Typical Hold Time | 51 Days | 109 Days |
Enterprise Value | $31.24B | $379.28B |
Dividend Yield | 1.16% | 6.11% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Verizon (VZ) trades at $41.115, down 10.17% over the past day, reflecting recent market pressure. The stock shows a bearish technical signal with key support at $45. Fundamentally, VZ maintains solid profitability with a 59.26% gross margin and has beaten earnings estimates in recent quarters. The company generates strong operating cash flow of $37.14 billion (2025) and offers a consistent dividend, with recent payouts of $0.71 per share. Analyst consensus is a 'Hold' with a $48.17 price target, indicating potential upside from current levels.
The outlook for VZ hinges on execution in the competitive telecom sector. Opportunities include stable cash flow supporting dividends and joint ventures expanding coverage. Risks involve high debt levels, with total debt at $144.01 billion, and pressure from rivals like T-Mobile. Earnings on October 26, 2026, will be critical for confirming growth trends amid economic uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →